Table 2.
Results of in vitro models with available IC50.
| Flavonol (Kaempferol, Fisetin, Myricetin) | Model (Prostate vs. Bladder Cancers) | Cell Line | Assay | IC50 (uM) | Reference |
|---|---|---|---|---|---|
| Kaempferol | Prostate cancer | LNCaP | MTT assay | 28.8 ± 1.5 μM (with 1 nM DHT) | [33] |
| PC-3 | 58.3 ± 3.5 μM (with 1 nM DHT) | ||||
| RWPE-1 | 69.1 ± 1.2 μM (with 1 nM DHT) | ||||
| DU-145 | Cell count with Trypan Blue | 38.35 ± 1.94 μM | [34] | ||
| PC-3 | 33.29 ± 2.96 μM | ||||
| LNCaP | WST-1 assay | 29 ± 6 μM | [35] | ||
| DU-145 | MTT assay | 50 ± 0.00 μM | [36] | ||
| PC-3 | WST-1 assay | 1.8 uM | [37] | ||
| Bladder cancer | EJ | MTT assay | 54.7 μM | [38] | |
| EJ | CCK-8 assay | 78.4 μM (T24 h) 38.1 μM (T48 h) | [47] | ||
| T24 | 85.3 μM (T24 h) 54.2 μM (T48 h) | ||||
| Fisetin | Prostate cancer | PC-3 | WST-1 assay | >50 μM | [52] |
| DU-145 | >50 μM | ||||
| LNCaP | 34.1 ± 7.7 μM | ||||
| LNCaP | CyQuant cell proliferation assay | 22.65 μM | [62] | ||
| PC-3 | 32.50 μM | ||||
| Myricetin | Prostate cancer | PC-3 | CCK-8 assay | 47.6 μM | [68] |
| DU-145 | 55.3 μM | ||||
| C4-2 | 79.9 μM | ||||
| RWPE1 | 362.1 μM | ||||
| PC-3 | MTT assay | 94.48 μM | [70] | ||
| Bladder cancer | SV-HUC SW-780 | CellTiterGlo reagent assay | >200 μM 20.9 μM |
[72] | |
| T24 | MTT assay | 85 μM | [73] |